Zelira Therapeutics Ltd

Perth-based Zelira Therapeutics (ASX: ZLD) has confirmed its cannabinoid-based diabetic nerve pain drug ZLT-L-007 has outperformed Pfizer’s commercially-available medication Lyrica (Pregabalin) in a multi-arm, head-to-head, US-based clinical trial. Zelira partnered with Pennsylvania-based global contract research organisation Affinity Bio Partners to manage the trial which involved 60 subjects to evaluate the efficacy, safety and tolerability of […]

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the ailing masses. But the path to the pharmacy is likely to be harder than they […]

Medical cannabis company Zelira Therapeutics (ASX: ZLD) has committed to a binding five-year agreement with US-based company Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise products to treat symptoms associated with peripheral arterial disease (PAD) and diabetic neuropathies (DPN). PAD is a circulatory condition in which narrowed arteries reduce blood flow to the limbs and […]

Zelira Therapeutics (ASX: ZLD) has announced its Phase 1b/2a medicinal cannabis trial to treat insomnia has met both its primary and secondary endpoints. The company today confirmed it has received the final clinical report for the trial, which shows its proprietary cannabis formulation ZTL-101 has produced “statistically significant and dose responsive improvements” in Insomnia Severity […]